A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemiaPadma Akkapeddi, Rita Fragoso, Julie A. Hixon, Ana Sofia Ramalho, Mariana L. Oliveira, Tânia Carvalho, Andreas Gloger, Mattia Matasci, Francisco Corzana, Scott K. Durum, ...
Kempeni, " Update on D2E7: a fully human anti-tumour necrosis factor -alpha monoclonal antibody " (2000) Ann. Rheum. Dis., 59(Supp1.1):1 44-145.Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody. Ann Rheum Dis 2000;59(suppl I):i44...
YUMAB, a global provider of fully human monoclonal antibodies, offers ultra-fast discovery and efficient lead development. The company is looking to expand its network of collaborators and clients through flexible licensing options for diagnostics and th
Animal models of CMTX1, such as transgenic mice expressing human Cx32 mutations [87, 88], will be essential for assessing the antibody’s efficacy under physiological conditions. Furthermore, our use of truncated Cx32 models for computational studies, while necessary for simplification, may ...
Figure 1.Isolation of GP-specific antibodies from immunized transgenic mice. (A) Immunization strategy of antibody-humanized transgenic mice, CAMouse. Each mouse was immunized with five injections of antigens comprised of EBOV GPΔmuc and rVSV-EBOV GP at 2-week intervals starting on day 0. An...
HBM1020 is a first-in-class fully human monoclonal antibody generated from Harbour Mice(®) H2L2 transgenic mice platform, targeting B7H7/HHLA2. B7H7, also known as HHLA2, is a novel immune modulatory molecule belonging to the B7 family. The B7 family is of central im...
Human monoclonal antibodies (MAbs) are needed for colon cancer radioimmunotherapy (RIT) to allow for repeated injections. Carcinoembryonic antigen (CEA) being the reference antigen for immunotargeting of these tumors, we developed human anti-CEA MAbs. Xe
Harbour BioMed announced that it has licensed its patented H2L2 fully human antibody discovery platform to Celsius Therapeutics.
(AML)andothermalignancies.WedescribethedevelopmentandcharacterizationofafullyhumanantibodytoCXCR4anditsapplicationfortherapyofAML,non-Hodgkin’slymphoma(NHL),chroniclymphoidleukemia(CLL),andmultiplemyeloma(MM).ExperimentalDesign:HumantransgenicmicewereimmunizedwithCXCR4expressingcellsandantibodiesreactivewithCXCR4were...
(Harbour Mice) for human antibody discovery. The company is building its proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and ...